NeoPharm Temettü
Temettü kriter kontrolleri 2/6
NeoPharm is a dividend paying company with a current yield of 2.65% that is well covered by earnings.
Anahtar bilgiler
2.7%
Temettü verimi
n/a
Geri Alım Getirisi
| Toplam Hissedar Getirisi | n/a |
| Gelecekteki Temettü Verimi | 2.7% |
| Temettü Büyümesi | 7.5% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | ₩375.000 |
| Ödeme oranı | 26% |
Son temettü güncellemeleri
Recent updates
NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13
NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Whilst dividend payments have been stable, A092730 has been paying a dividend for less than 10 years.
Büyüyen Temettü: A092730's dividend payments have increased, but the company has only paid a dividend for 5 years.
Piyasaya Karşı Temettü Getirisi
| NeoPharm Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (A092730) | 2.7% |
| Pazarın Alt %25'i (KR) | 1.2% |
| Pazarın En İyi %25'i (KR) | 3.8% |
| Sektör Ortalaması (Personal Products) | 1.0% |
| Analist tahmini (A092730) (3 yıla kadar) | 2.7% |
Önemli Temettü: A092730's dividend (2.65%) is higher than the bottom 25% of dividend payers in the KR market (1.18%).
Yüksek Temettü: A092730's dividend (2.65%) is low compared to the top 25% of dividend payers in the KR market (3.75%).
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: With its reasonably low payout ratio (25.6%), A092730's dividend payments are well covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: A092730 is paying a dividend but the company has no free cash flows.